The cytotoxic drugs used in ADCs are required to be highly potent, normally 10-1000 folds higher than those first-line chemotherapy drugs in use. According to the cell-killing mechanism, these cytotoxic drugs can be classified into several categories, including microtubule inhibitor/stabilizer, DNA binding/alkylating agent, DNA topoisomerase, RNA polymerase, etc.
NewBio Therapeutics has developed a series of proprietary high-potency cytotoxic drugs derivatized from Dolastatin 10. The potencies of new derivatives are superior to those of the similar type currently used in ADCs in clinical trials and/or market.